Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

Abstract

Objective:

To examine the impact of baseline severity on lisdexamfetamine dimesylate (LDX) efficacy in a long-term study of adults with attention-deficit/hyperactivity disorder (ADHD).     

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands

Abstract

Objective:

To evaluate the number of patients reaching stable treatment with a stimulant (methylphenidate or dexamphetamine) or non-stimulant (atomoxetine) attention-deficit/hyperactivity disorder (ADHD) medication approved for use in the Netherlands, and the time to treatment stabilization among children and adolescents aged 6–17 years.     

Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine

Abstract

Background:

Attention-deficit/hyperactivity disorder (ADHD) and substance use disorder are often comorbid in adults. The effects of ADHD treatment on comorbid alcohol use disorder have not been extensively studied.     

Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

Abstract

Objective:

Short-term clinical trials have demonstrated the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD). This study examined long-term safety and tolerability of pregabalin in patients with GAD, social anxiety disorder (SAD), or panic disorder (PD).     

Treatment adherence and persistence with duloxetine,venlafaxine XR,and escitalopram among patients with major depressive disorder and chronic pain-related diseases

Abstract

Objective:

Chronic pain is prevalent in patients with major depressive disorder (MDD). This study compared adherence and persistence rates among MDD patients with comorbid chronic pain-related diseases (CPD, including fibromyalgia, diabetes with neurological manifestations, osteoarthritis, low back pain, and headache) for three antidepressants: duloxetine, venlafaxine XR, and escitalopram.     

Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders

Abstract

Objective:

This post hoc analysis examined efficacy and tolerability of open-label desvenlafaxine in patients with major depressive disorder switched from blinded placebo, venlafaxine extended release (ER), or desvenlafaxine.     

Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study

Abstract

Objective:

To examine the predictors of duloxetine monotherapy versus other antidepressants among patients with major depressive disorder (MDD) in the Veterans Health Administration (VHA).     

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

Abstract

Objective:

The primary objective of this study was to evaluate the safety and tolerability of the investigational drug vortioxetine (Lu AA21004) in the long-term treatment of patients with major depressive disorder.     

Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review

Abstract

Objectives:

Tuberous sclerosis complex (TSC) is a progressive genetic disorder characterized by pervasive benign tumor growth. We sought to assess the current understanding of burden of TSC-related neurological manifestations.     

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

Abstract

Objective:

This study measured the effects of atomoxetine HCl on high-risk behaviors and health-related quality of life in adolescents with attention-deficit/hyperactivity disorder (ADHD), using a subgroup analysis of data from a previous clinical trial.     

Comprehensive review of generalized anxiety disorder in primary care in Europe

Abstract

Objective:

This review aims to summarize meta-analyses and other relevant data relating to the efficacy and safety of the various treatment options for generalized anxiety disorder (GAD) in Europe. In addition, it will provide an overview of the prevalence, burden, and recognition of the disorder, with a view to raise awareness of GAD and inform primary care practitioners.     

HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system

Abstract

Objective:

To evaluate the impact of methylphenidate transdermal system (MTS) on health-related quality of life (HRQL) and medication satisfaction in children with attention-deficit/hyperactivity disorder (ADHD) as well as to identify potential moderators of HRQL and medication satisfaction.     

Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center,randomized, controlled,single-blind,right-vs.-left study in comparison with standard glycerol-based emollient cream

Abstract

Background:

Ichthyoses are genetic disorders of keratinization which are uncomfortable due to their conspicuous scaling, itching and cosmetic problems. Ichthyoses can lead to social discrimination and psychological problems. Ichthyosis vulgaris (IV) is the most common form of these geno-dermatoses. IV is a chronic disorder that often requires continuous therapy. Emollient and keratolytic products are the mainstay treatments of IV. It is important that efficient, safe and well tolerated therapies should be available. Direct comparative data regarding efficacy of different emollient products in IV patients are very few.     

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder

Abstract

Objective:

Treatment-resistant depression (TRD) imposes substantial cost from the perspective of employers. The objective of this study was to assess direct healthcare costs and indirect (disability and medical-related absenteeism) costs associated with TRD compared with non-treatment-resistant major depressive disorder (MDD).     

Low prevalence of hyponatremia codification in departments of internal medicine and its prognostic implications

Abstract

Objective:

Hyponatremia is the most frequent ionic disorder among ambulatory and hospitalized populations. The aim of the study is to describe the profile of patients admitted to internal medicine departments of Spanish hospitals with a diagnostic codification of hyponatremia in their discharge sheets.     

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study

Abstract

Objective:

Painful physical symptoms are common in patients with major depressive disorder (MDD) and can negatively affect patient outcomes. Duloxetine has demonstrated efficacy in treating MDD and other certain painful conditions; this study specifically evaluated patients with both MDD and MDD-associated pain.     

Health-related quality of life,work productivity and health care resource use associated with constipation predominant irritable bowel syndrome

Abstract

Objectives:

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Prevalence estimates of IBS vary widely, from 10 to 15%, in the U.S. However, few studies have examined constipation predominant IBS (IBS-C), a subtype of IBS. The aim of this study was to assess the effect of IBS-C on health-related quality of life (HRQOL), work productivity and activity impairment, and health care resource use.     

Safety,tolerability, pharmacokinetics and pharmacodynamics of albiglutide,a long-acting GLP-1-receptor agonist,in Japanese subjects with type 2 diabetes mellitus

Abstract

Objective:

To investigate safety, pharmacokinetics and pharmacodynamics of albiglutide in Japanese subjects with type 2 diabetes mellitus.     

Factors associated with warfarin discontinuation,including bleeding patterns,in atrial fibrillation patients

Abstract

Objective:

To determine risk factors for both warfarin discontinuation and bleeding in patients with atrial fibrillation (AF).